Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins
29 May 2019: Norwich, UK Leaf Expression Systems, a contract development and manufacturing organisation specialising in the plant-based expression and production of proteins, vaccines, metabolites and complex natural proteins, has announced the launch of its online list of products available for purchase by researchers working within the life sciences and agricultural industries.
The products are produced in Nicotiana benthamiana using Hypertrans®, Leaf’s Agrobacterium-mediated transient…
Following the continued success of Pharma Integrates, the inaugural Bio Integrates event took place on 22nd May in London. The sold-out conference hosted 315 delegates from across biotech, pharma, investment, charities and patient groups.
The event was opened by Darrin Disley OBE, Chief Executive Officer of Mogrify, who highlighted the importance of collaboration across the science and technology in its ability to deliver effective, affordable and scalable healthcare solutions. He also set the delegates three inspirational challenges: to create an ecosystem of innovation and aspiration; to…
AMSBIO introduces StemFit® Basic04, a next generation feeder-free medium for the maintenance of Induced Pluripotent Stem (iPS) and Embryonic Stem (ES) cells during the reprogramming, expansion and differentiation phases of stem cell culture. With its fully defined and animal-origin free formulation, StemFit® Basic04 is suited to both research studies and translation to cell therapy.With the new StemFit® Basic04 it is now possible to experience market-leading colony expansion (scalable 100-fold expansion / week) allowing single-cell cloning and consistent high performance with a range of…
SOMERSET, N.J. – May 23, 2019 — Catalent (Booth 3101), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is to launch its new OneBio SuiteSM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention, which takes place at the Pennsylvania Convention Center in Philadelphia, from June 3-6, 2019.
OneBio has been designed specifically to address the challenges facing biologic development companies that are looking to accelerate programs to clinic…
The word “undruggable” has hampered pursuit of the most compelling biological targets, drawing from established opinion that pharmacological modulation was not possible. Scientists at Dogma Therapeutics (“Dogma”) were determined to challenge this assumption. Dogma has discovered an orally-bioavailable small molecule PCSK9 inhibitor. By strategically focusing on small molecule inhibitors, Dogma can readily combine their compounds with current standard of care and dramatically disrupt the health economics of PCSK9-based therapies.
Several antibody-based inhibitors emerged following the rapid…
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million investment. The additional funding from Mercia Technologies PLC, the national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high growth potential, is part of a circa £2.4 million syndicated investment round.
The global transdermal drug delivery market in which Medherant operates is…
London, UK, 21st May 2019 / The £27m UK Innovation & Science Seed Fund (UKI2S) and Innovate UK (IUK) have launched a joint initiative, the UKI2S Innovate Accelerator. With £10m of IUK funding to be used alongside direct equity investment by UKI2S, the new scheme is designed to boost some of the UK’s most exciting young companies.
The UKI2S Innovate Accelerator combines the technology assessment and grant funding capabilities of Innovate UK with equity funding from UKI2S, one of the UK’s leading seed-stage investors. It has been created to help companies accelerate their innovation,…
Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and an extended programme of mentoring and support
Babraham 21st May 2019: Eight finalists; life science ventures covering the fields of new therapeutics, diagnostics, medical devices and manufacturing pitched head-to-head to a distinguished judging panel and an invited audience on Wednesday, May 15th, for the chance to join the Babraham Research Campus community as part of the 5-month 2019 Accelerate@Babraham programme.
The final followed on from the Babraham…
TTP enables development of MosaiQ™ diagnostic platform for transfusion typing and disease screening
Cambridge, UK, 20 May 2019: TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with Quotient Ltd (NASDAQ:QTNT), a commercial-stage diagnostics company committed to transforming transfusion diagnostics and beyond – to develop and implement a state-of-the-art manufacturing facility for Quotient’s proprietary MosaiQ™ system.
MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully…
Cambridge, UK, 20 May 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension (PAH), to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes. This development program will be solely funded by Actelion.
Pulmonary hypertension (PH) is a progressive…